TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04433260

Intervention type: OTHER
Intervention: Questionnaire, same tools as before, with inclusion of PCL5 questionnaire too.
Description: Follow-up electronic surveys including questions regarding affective symptoms, behavioural changes and mental well-being will be sent at 6-weeks and 4-months following the initial survey. This will be sent to participants from Groups 1-3 that provided consent to receive these follow-up questionnaires.

Intervention type: OTHER
Intervention: Questionnaire, same tools as before, with inclusion of PCL5 questionnaire too.
Description: Follow-up electronic surveys including questions regarding affective symptoms, behavioural changes and mental well-being will be sent at 6-weeks and 4-months following the initial survey. This will be sent to participants from Groups 1-3 that provided consent to receive these follow-up questionnaires.

Intervention type: OTHER
Intervention: Questionnaire, same tools as before, with inclusion of PCL5 questionnaire too.
Description: Follow-up electronic surveys including questions regarding affective symptoms, behavioural changes and mental well-being will be sent at 6-weeks and 4-months following the initial survey. This will be sent to participants from Groups 1-3 that provided consent to receive these follow-up questionnaires.
Study: NCT02487589

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone support, telemonitoring and tele-exercise
Description: The care model will provide 24/24 h assistance for six months and include:~Telephone Support: a nurse-tutor (NT) will follow-up the enrolled patients weekly mainly through scheduled appointments. NTs duties will be: 1 education (patients and family ' s health education on how to prevent falls, verification of the adherence to the pharmacological therapy, teaching on how to recognize problems that can conduct to falls) and 2. management. Occasional appointments will be required by patients on duty and managed by a nurse .~Telemonitoring: all patients will send proper biological traces and data will be registered on a personal health record.~Tele-exercise: Home exercises sessions will be provided by a DVD and monitored through a videoconference by a physiotherapist.
Study: NCT01794104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMP400
Description: Top1 inhibitors such as LMP400 are potent anticancer agents because stabilizing cleavage complex formation induces replication-and transcription-mediated DNA damage and delays DNA repair, leading to apoptosis. Preclinical and clinical data indicate that baseline tumor levels of Top1 correlate strongly with ability to respond to Top1 inhibitor therapy.
Study: NCT01973101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 50 mg/m2 - Day 1
Study: NCT02565745

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moisturizing cream
Description: It will be applied twice a day to the same skin areas as the experimental group
Study: NCT01973101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2 on day 1 and day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin 40 mg/m2 on day 1, day8, day15, day22, day 36 of radiotherapy period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Cisplatin 40 mg/m2 on day 1, day8, day15, day22, day 36 of radiotherapy period.
Study: NCT02321111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eritoran
Description: Eritoran = E5564 Eritoran is a pharmacologic inhibitor of TLR4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D5W (5% Dextrose in water)
Description: D5W = 5% Dextrose Water Vehicle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D5W (5% Dextrose in water)
Description: D5W = 5% Dextrose Water Vehicle
Study: NCT02012322

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Coenzyme Q10
Description: 100mg/day for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Coenzyme Q10
Description: 100mg/day for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Coenzyme Q10
Description: 100mg/day for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Coenzyme Q10
Description: 100mg/day for three months
Study: NCT01973101

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 45 Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 45 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: 80 Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy
Description: 80 Gy
Study: NCT02351869

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous Oxide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Study: NCT02386943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 100mg po once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: 5mg po once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blank control
Description: No medication is taken.
Study: NCT01769885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tivozanib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo nephrectomy
Study: NCT00940303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 3200mg/m2 continuous iv infusions, day 1 every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 5mg/kg iv infusion, day 1 every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: 165mg/m2 iv infusion, day 1 every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: 200mg/m2 iv infusion, day 1 every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 85mg/m2 iv infusion, day 1 every 2 weeks
Study: NCT00203749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-Based HIV VCT
Description: COMMUNITY MOBILIZATION. This component of the intervention uses community outreach to enhance the uptake of VCT, thus increasing the rate of HIV testing and frequency of discussions about HIV and reducing stigma through community education and mobilization.~EASY ACCESS TO VCT. This component is designed to remove practical barriers and increase safety of VCT. Mobile vans or temporary units set up at local community sites will provide free, anonymous VCT in specific, chosen sites where people gather, such as market areas, shopping centers, and community centers.~POST-TEST SUPPORT SERVICES. This component is designed to build psychosocial support to improve the quality of life for individuals diagnosed with HIV. The expected outcomes include a reduction in social harm, an increase in social support through disclosure to those most likely to provide support, and a reduction in internalized stigma. Social support should also decrease the behavioral risk of further transmission.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard clinic-based VCT
Description: Control communities will receive Standard Clinic-Based VCT (SVCT) instead of the community-based VCT (CBVCT) intervention. Each of these communities will have access to SVCT that reflects local access to health care. The training for VCT counselors will be the same in the CBVCT and SVCT communities; however, no active recruitment for participation in the SVCT services will be made beyond the standard procedures of each clinic for informing patients of services (e.g., telling individual patients that VCT is available, posting of a flyer in the clinic announcing VCT availability, etc). As such, no active outreach or community mobilization will be conducted by the study staff in the SVCT settings (although it is possible that such activities will occur due to local initiative).
Study: NCT02808845

Intervention type: OTHER
Intervention: microalbuminuria

Intervention type: OTHER
Intervention: microalbuminuria
Study: NCT01194024

Intervention type: OTHER
Intervention: Standard of Care
Description: bronchoscopy with collection of bronchioalveolar lavage specimen, blood samples, High-Resolution spiral computed tomography(CT)
Study: NCT01007695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Valproic Acid is FDA approved and indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic Acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures.
Study: NCT01493271

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to RO5093151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5093151
Description: oral doses twice daily for up to 28 days
Study: NCT02224365

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Apple
Description: 12 weeks of 75 g dried apple powder taken in 480 ml per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 weeks of 75 g apple-flavored placebo powder taken in 480 ml per day.
Study: NCT01826500

Intervention type: OTHER
Intervention: blood test
Description: blood test

Intervention type: OTHER
Intervention: blood test
Description: blood test
Study: NCT01637688

Intervention type: DIETARY_SUPPLEMENT
Intervention: Comparison of treatment with different amino acid formulas
Description: Growth and amino acid status of a newly innovated amino acid formula (NAAF) and a commercial amino acid formula (AAF)
Study: NCT02662023

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bolus
Description: A transversus abdominis catheter was inserted and ropivacaine 0.2% administered as two separate bolus doses of 24 mL each: one at time point zero and one 3 hours later.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bolus
Description: A transversus abdominis catheter was inserted and ropivacaine 0.2% administered as two separate bolus doses of 24 mL each: one at time point zero and one 3 hours later.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basal
Description: A transversus abdominis catheter was inserted and ropivacaine 0.2% administered as a continuous basal infusion (8 mL/h) from time point zero for the following 6 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basal
Description: A transversus abdominis catheter was inserted and ropivacaine 0.2% administered as a continuous basal infusion (8 mL/h) from time point zero for the following 6 hours.
Study: NCT01424488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: Anesthetised patients will receive a single intubation dose of succinylcholine (1.0 mg/kg) and maintenance bolus dose of pipecuronium (0.08 mg/kg) to maintain the level of neuromuscular blockade at reappearance of T2 Sugammadex in the dose of 4 mg/kg is to be administered as an intravenous bolus dose at the level of neuromuscular blockade of reappearance of T2 (moderate blockade) by means of TOF-Watch SX after the last dose of pipecuronium according to randomization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Anesthetised patients will receive a single intubation dose of succinylcholine (1.0 mg/kg) and maintenance bolus dose of pipecuronium (0.08 mg/kg) to maintain the level of neuromuscular blockade at reappearance of T2. 3,0 ml of saline (placebo) is to be administered as an intravenous bolus dose at the level of neuromuscular blockade of reappearance of T2 (moderate blockade) by means of TOF-Watch SX after the last dose of pipecuronium according to randomization
Study: NCT01371656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levofloxacin
Description: Given PO or IV
Study: NCT02321696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy and eccentric exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Watchful waiting and eccentric exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eccentric exercise
Study: NCT00127140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Study: NCT00637195

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™)
Description: Intramuscular administration, 3 doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™
Description: Intramuscular administration, 4 doses.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™
Description: Intramuscular administration, 4 doses.
Study: NCT01575327

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated settings on the oxygen delivery device
Description: FreeO2 automatically adjusts the oxygen flow delivered to patients based on the SpO2 signal and collects the cardiorespiratory parameters

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual settings with FreeO2 system in collection mode
Description: FreeO2 system does not adjust oxygen flow but collects the cardiorespiratory parameters
Study: NCT02133729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling and OGTT
Study: NCT02471521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mask ventilation
Description: Mask ventilation is performed after administration of rocuronium or not. Initial inspiratory pressure is set as 10 cmH2O and increased gradually by 2 cmH2O until gastric insufflation is detected by either of two methods. Tracheal intubation is done after detection of gas.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mask ventilation
Description: Mask ventilation is performed after administration of rocuronium or not. Initial inspiratory pressure is set as 10 cmH2O and increased gradually by 2 cmH2O until gastric insufflation is detected by either of two methods. Tracheal intubation is done after detection of gas.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Rocuronium 0.6 mg/kg is injected before mask ventilation in muscle relaxant group or after finish of study in non-relaxant group.
Study: NCT00957437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1305
Description: Single Oral Dose, ER formulation 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1305
Description: ER formulation 1, bid for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1305
Description: Single Oral Dose, ER formulation 2
Study: NCT03074903

Intervention type: DEVICE
Intervention: Intrauterine system
Description: Women having the Skyla intrauterine system at different times during their menstrual cycle report their bleeding patterns through daily texts.

Intervention type: DEVICE
Intervention: Intrauterine system
Description: Women having the Skyla intrauterine system at different times during their menstrual cycle report their bleeding patterns through daily texts.
Study: NCT02130765

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac catheter ablation with ICD/CRT-D
Description: Cardiac ablation catheter system
Study: NCT03326427

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skill Training Group of the Dialectical Behavior Therapy
Description: A 12 session version of the Skill Training Group of the Dialectical Behavior Therapy, adapted for treatment of ADHD.
Study: NCT04433260

Intervention type: OTHER
Intervention: Informed consent
Description: Participants will need to give their consent to participate to the survey after reading PIS

Intervention type: OTHER
Intervention: Informed consent
Description: Participants will need to give their consent to participate to the survey after reading PIS

Intervention type: OTHER
Intervention: Informed consent
Description: Participants will need to give their consent to participate to the survey after reading PIS

Intervention type: OTHER
Intervention: Informed consent
Description: Participants will need to give their consent to participate to the survey after reading PIS

Intervention type: OTHER
Intervention: Informed consent
Description: Participants will need to give their consent to participate to the survey after reading PIS
Study: NCT02304302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Encapsulated Namenda 10 mg bid (after four-week standard dose titration protocol)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically looking placebo capsules bid (after a four-week regimen designed to mimic standard dose titration protocol)
Study: NCT04034524

Intervention type: DRUG
Intervention: GLP-1 receptor agonist
Description: any GLP-1 receptor agonist (other than Saxenda or liraglutide 3.0mg)

Intervention type: DRUG
Intervention: Insulin
Description: glargine, detemir, neutral protamine Hagedorn (NPH), degludec
Study: NCT03326427

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Conventional protocol using only medication (including drug adherence).
Study: NCT00775437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab solution for injection for subcutaneous use.
Study: NCT02388997

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omalizumab
Description: This medication has been approved for clinical use to treat patients with moderate to severe asthma by the FDA in 2003 and for use in this study (BB-IND# 10510)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: omalizumab
Description: This medication has been approved for clinical use to treat patients with moderate to severe asthma by the FDA in 2003 and for use in this study (BB-IND# 10510)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rhinovirus (strain 16)
Description: This strain of pooled rhinovirus has been approved for use in experimental challenges (BB-IND# 15162) and for use in this study (BB-IND# 10510) by the FDA.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rhinovirus (strain 16)
Description: This strain of pooled rhinovirus has been approved for use in experimental challenges (BB-IND# 15162) and for use in this study (BB-IND# 10510) by the FDA.
Study: NCT03638986

Intervention type: OTHER
Intervention: No intervention planned
Description: No Intervention planned.

Intervention type: OTHER
Intervention: No intervention planned
Description: No Intervention planned.
Study: NCT04252105

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant
Description: Antioxidant-rich diet (added selected types of fruits, vegetables, nuts, cereals and oils)
Study: NCT03083691

Intervention type: DRUG
Group type: OTHER
Intervention: Nivolumab, Ipilimumab
Description: Cohort 1: addition of ipilimumab in case of progression on nivolumab monotherapy.

Intervention type: DRUG
Group type: OTHER
Intervention: Nivolumab, Ipilimumab
Description: Cohort 2: upfront combination therapy of nivolumab and ipilimumab for four cycles, followed by nivolumab monotherapy.
Study: NCT03743948

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Non invasive prenatal diagnosis
Description: 15 pregnant women and their spouses Search for the familial mutation on isolated circulating fetal trophoblastic cells from maternal blood
Study: NCT00806468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmotabs
Description: Desmotabs encapsulated, 0,2 mg once daily for one week, 0,2 mg bid for one week
Study: NCT00006184

Intervention type: DRUG
Group type: OTHER
Intervention: Myeloma Immunoglobulin Idiotype Vaccine
Description: 3 subcutaneous (SC) injections of myeloma protein within 10 weeks before stem cell collection the first (week 0), second (week 2), and third injection (week 6) with Id-KLH (0.5 mg SC day 1)

Intervention type: DRUG
Group type: OTHER
Intervention: Bortezomib
Description: Induction chemotherapy: 1.3 mg/m\^2 bolus intravenous injection twice weekly for 2 weeks (days 1, 4, 8, 11) followed by 10 day rest period (day 12-21)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Induction chemotherapy: 1.3 mg/m\^2 bolus intravenous injection twice weekly for 2 weeks (days 1, 4, 8, 11) followed by 10 day rest period (day 12-21)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Induction chemotherapy: 600 mg/m\^2 day 4 Transplant: 1200 mg/m\^2 intravenous x 4 days (days -6, -5, -4, -3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Transplant: 2 mg/kg intravenous every 12 hours continuous intravenous or by mouth (PO) until day + 180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride
Description: Induction chemotherapy: 10 mg/m\^2 day continuous intravenous (CIV) days 1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Induction chemotherapy: 50 mg/m\^2 day continuous intravenous days 1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Induction chemotherapy: 25 mg/m\^2 day intravenous days 1-3 Transplant: 30 mg/m\^2 day x 4 days (days -6, -5, -4, -3 )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 60 mg/m\^2 day 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Induction chemotherapy: 0.5 mg/m\^2 day continuous intravenous days 1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Transplant: 5 mg/m\^2 intravenous on days +1, +3, +6, +11

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: GMCSF (granulocyte macrophage colony stimulating factor)
Description: 250 mcg/m\^2 subcutaneously every day, days 1-4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GCSF (granulocyte colony stimulating factor)
Description: 10 mcg/kg per day subcutaneously daily from day 5 until absolute neutrophil count (ANC) \> 1000/ul x 2 days
Study: NCT00167934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate
Description: Depakote ER 500 mg to 3000 mg taken every night

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given at same frequency as Valproate
Study: NCT03357406

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound implant site preparation
Description: piezoelectric bone surgery will be used to create implant bone ostectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional implant site preparation
Description: twist drills will be used to create implant bone ostectomy
Study: NCT00581282

Intervention type: RADIATION
Intervention: PET scan
Description: positron emission tomography PET scan

Intervention type: RADIATION
Intervention: PET scan
Description: positron emission tomography PET scan

Intervention type: OTHER
Intervention: fMRI
Description: functional magnetic resonance imaging fMRI

Intervention type: OTHER
Intervention: fMRI
Description: functional magnetic resonance imaging fMRI